[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:t-cell-prolymphocytic-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":80,"states":81},"T-Cell Prolymphocytic Leukemia",11,9,[8,16,23,29,35,41,47,54,60,66,73],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07311746","Phase Ib\u002FII Trial of Cladribine\u002FRuxolitinib\u002FVenetoclax in Patients With Relapsed\u002FRefractory T-cell Prolymphocytic Leukemia",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:29.711989Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04496349","A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R\u002FR T-PLL and NHL",[20],"Phase 2","2026-08-26T02:16:38.897933Z","2026-04-29T02:57:57.115952Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07356245","Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma",[20],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.624777Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:18:40.612983Z","2026-07-30T01:46:14.462113Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[20],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT04771572","Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS\u002FMPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",[51],"Phase 1","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.598768Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[51],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":74,"title":75,"phases":76,"status":77,"updated_at":78,"content_modified":79},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[51],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[82,86,90,93],{"state":83,"count":84,"slug":85},"Texas",7,"texas",{"state":87,"count":88,"slug":89},"Massachusetts",3,"massachusetts",{"state":91,"count":88,"slug":92},"New York","new-york",{"state":94,"count":88,"slug":95},"Ohio","ohio"]